title: Emerging therapies for neuropathic pain.
abstract: Neuropathic pain develops as a result of damage to either the peripheral or central nervous system. It is characterised by spontaneous burning pain and/or ongoing pain with accompanying hyperalgesia and allodynia. Neuropathic pain is difficult to treat as it is often refractory to conventional analgesic treatments, with most patients obtaining only partial relief. At present, there are four major medication categories that are considered first-line treatment for neuropathic pain: antidepressants, anticonvulsants, local anaesthetic/topical agents and opioids. The efficacy of these treatments in neuropathic pain, excepting opioids, has been discovered serendipitously. However, responder rates and overall efficacy is poor with these agents and tolerability or side effects are often limiting. This update will review existing treatment options for neuropathic pain, and highlight more recent advances in the development of novel analgesics to treat this chronic disorder.
authors.affiliation: GlaxoSmithKline, Neurology & Gastrointestinal Centre of Excellence for Drug Discovery, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK. Sue.D.Collins@gsk.com
authors.forename: Susanne D
authors.initials: SD
authors.lastname: Collins
authors.forename: Iain P
authors.initials: IP
authors.lastname: Chessell
mesh_terms: D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic / Q000639:trends; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000473:pathology; D011115:Polyneuropathies / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000700:Analgesics; D015507:Drugs, Investigational